<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<!--<?xml-stylesheet type="text/xsl" href="article.xsl"?>-->
<article article-type="research-article" dtd-version="1.0" xml:lang="en"
    xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <front>
        <journal-meta>
            <journal-id journal-id-type="issn">0973-7510</journal-id>
            <journal-title-group>
                <journal-title>Journal of Pure and Applied Microbiology</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2581-690X</issn>
            <publisher>
                <publisher-name>DR. M.N. Khan</publisher-name>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.22207/JPAM.20.2.44</article-id>
            <title-group>
                <article-title>Anti-Helicobacter pylori Activity of Quinolin-2-one/Chalcone Hybrids as Urease Inhibitors</article-title>
            </title-group>
            <contrib-group>

				<contrib contrib-type="author">
                    <name>
                        <surname>Alzahrani</surname>
                        <given-names>Hayat Ali</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff-1"/>
                </contrib>
				
			</contrib-group>


          <aff id="aff-1">Applied Medical Science College, Medical Laboratory Technology Department, Northern Border University, Arar, Saudi Arabia.</aff>



            <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-06-04">
                <day>04</day>
				<month>06</month>
                <year>2026</year>
            </pub-date>
            <volume></volume>
            <issue></issue>
            <fpage></fpage>
            <lpage></lpage>
            <permissions>
                <copyright-statement>Copyright &#x00A9; 2026 The Author(s)</copyright-statement>
                <copyright-year>2026</copyright-year>
                <license license-type="open-access"
                    xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.<uri
					xlink:href="https://creativecommons.org/licenses/by/4.0/"
                            >https://creativecommons.org/licenses/by/4.0/</uri></license-p>
                </license>
            </permissions>
            <self-uri xlink:href="https://microbiologyjournal.org/anti-helicobacter-pylori-activity-of-quinolin-2-one-chalcone-hybrids-as-urease-inhibitors/"/>
            <abstract>
                <p>The present research explores the urease inhibitory potential of a designed set of quinoline-2-one/chalcone hybrid derivatives (4a-e). The biological assessment demonstrated that these molecules exhibit strong urease inhibition, with IC50 values ranging from 0.58-1.90 µM. Their inhibitory potency notably surpasses that of the reference compound, thiourea (IC50 = 21.50 µM). Within this series, compounds 4a, 4c, and 4e emerged as the most active inhibitors, displaying IC50 values of 0.93 ± 0.08 µM, 0.75 ± 0.06 µM, and 0.58 ± 0.04 µM, respectively. In addition, the anti-Helicobacter pylori potential of these hybrids was assessed against three metronidazole-resistant H. pylori strains using the disk diffusion technique. The outcomes revealed a strong association, indicating that methoxy-bearing analogs 4c and 4e identified as the most effective urease inhibitors also exhibited pronounced antibacterial action against H. pylori. Collectively, these observations underscore the promising dual therapeutic profile of this hybrid framework.</p>
		</abstract>
		<kwd-group>
        <title>Keywords</title>
        <kwd>Urease</kwd>
        <kwd>Helicobacter pylori</kwd>
        <kwd>Antibacterial</kwd>
        <kwd>Paper Disk</kwd>
        <kwd>Inhibition Zone</kwd>
		</kwd-group>
</article-meta>
</front>
</article>
